APLS vs. VTRS, ROIV, QGEN, ELAN, BBIO, MRNA, VRNA, RVMD, GRFS, and RYTM
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Viatris (VTRS), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Grifols (GRFS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.
Apellis Pharmaceuticals vs. Its Competitors
Viatris (NASDAQ:VTRS) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.
Viatris currently has a consensus price target of $10.40, indicating a potential upside of 2.56%. Apellis Pharmaceuticals has a consensus price target of $33.29, indicating a potential upside of 32.07%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Viatris.
79.9% of Viatris shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 0.1% of Viatris shares are held by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Apellis Pharmaceuticals had 4 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Apellis Pharmaceuticals and 2 mentions for Viatris. Viatris' average media sentiment score of 0.68 beat Apellis Pharmaceuticals' score of 0.12 indicating that Viatris is being referred to more favorably in the media.
Viatris has a net margin of -24.57% compared to Apellis Pharmaceuticals' net margin of -30.24%. Viatris' return on equity of 16.54% beat Apellis Pharmaceuticals' return on equity.
Apellis Pharmaceuticals has lower revenue, but higher earnings than Viatris. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.
Viatris has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Summary
Apellis Pharmaceuticals beats Viatris on 10 of the 17 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:APLS) was last updated on 10/7/2025 by MarketBeat.com Staff
